Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S43, 2018. DOI: 10.25251/skin.2.supp.43. Disponível em: https://skin.dermsquared.com/skin/article/view/291. Acesso em: 19 apr. 2025.